Brief: Alterity Therapeutics Gets Authorization In France & Austria To Proceed With Phase 2 Clinical Trial
16/02/2023 01:43
Feb 16 (Reuters) - Alterity Therapeutics Ltd ATH.AX :
* RECEIVES REGULATORY AUTHORIZATION IN FRANCE AND AUSTRIA TO
PROCEED WITH ATH434 PHASE 2 CLINICAL TRIAL
Source text for Eikon: ID:nASX8dXh4g
Further company coverage: ATH.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital